NCT06926218View on ClinicalTrials.gov

This Study is to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of HSK47388 in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

September 30, 2025

Conditions

Healthy

Interventions

DRUG

HSK47388

cohort 1 to cohort 5

DRUG

Placebo

cohort 1 to cohort 5

Trial Locations (1)

Unknown

CMAX Clinical Research, Adelaide

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY